Can patients with bridge onychiasis and hypothyroidism have normal childbearing?
Medical
-
-
-
With the continuous development of science and technology, a series of new myopia correction operations have emerged in the field of ophthalmology. After surgery, myopia patients can also achieve the vision effect when wearing glasses without wearing glasses. Excimer laser surgery, which has been carried out in the last two decades, has the advantages of high efficiency, accuracy and safety.
-
Medical
New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results
The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.
-
Afamitresgene Autoleucel, also known as Afami-cel or ADP-A2M4, is a novel TCR-T cell immunotherapy that has produced durable and promising results in patients with advanced synovial sarcoma or mucinous/round cell liposarcoma
-
Medical
New Technology Can Break The Blood-Brain Barrier To Directly Treat Brain Tumours, Is Potent And Less Toxic, And Deserves Attention!
For brain cancer, the major obstacle to treatment is not the tumour, but the brain itself. How to break the "blood-brain barrier" and allow effective anti-cancer drugs to enter the brain to take effect has long been a key issue in brain cancer treatment. Recently, a new study has shown that a new type of pump can be implanted in brain cancer patients to safely break the blood-brain barrier and better treat brain cancer!
-
Medical
K-Drug Approved For Adjuvant Treatment Of Early-Stage Non-Small Cell Lung Cancer, Significantly Extending Cancer-Free Survival Of Patients!
The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.
-
Latest real-world data published, providing real evidence of the effectiveness of Azulfidine in patients with COVID-19
-
Medical
New Treatment For Childhood Brain Tumours, Tovorafenib, Shows Promising Results With An Efficiency Rate Of 91%!
According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.
-
Medical
Study Shows Drug Halves Recurrence Rate In Patients With Early-Stage EGFR-Mutated Lung Cancer!
A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!